EffPha Has Officially Been Recognized on the IDA MOEA’s CRO Reference List, Helping Biotech & Pharma Enterprises Utilize Their Funds More Flexibly

Efficient Pharma Management Corp. has received approval from the Industrial Development Administration (IDA) of the Ministry of Economic Affairs (MOEA), being included in the “Investment Tax Credit on Research and Development Expenses of Biotech and Pharmaceutical Industry Entrusted to Domestic Pharmaceutical R&D Service Companies” (also known as Contract Research Organization) reference list. This was officially announced on the IDA MOEA’s website on October 25, 2024.

Biotech and pharmaceutical companies that meet the criteria set forth in:

• “Article 5 of the Act for the Development of Biotech and Pharmaceutical Industry and the Investment Tax Credit Regulations on Research and Development Expenses of Biotech and Pharmaceutical Industry”,
• “Article 10 of the Statute for Industrial Innovation and the Investment Tax Credit Regulations on Research and Development Expenses of Companies or Limited Partnerships”, or
• ” Article 35 of the Act for Development of Small and Medium Enterprises and the Investment Tax Credit Regulations on Research and Development Expenses of Small and Medium Enterprises”,

and spend service fees for entrusting EffPha to engage in non-clinical and clinical trial stages related to the research and development of medicinal products, may be eligible to apply for an income tax deduction for the same fiscal year. This tax deduction program can help biotech and pharmaceutical enterprises engaged in drug development to utilize their funds more flexibly!

EffPha, led by President and CEO, Dr. Frank Shen, not only helps biotech and pharmaceutical industry partners to manage their funds flexibly, but also continues to collaborate with the drug development experts from the world's top ten pharmaceutical companies to share insights from successful drug development projects worldwide. By doing so, EffPha empowers domestic and international biotech companies to pursue new drug development with a more forward-looking strategy, strives together to achieve new heights in pharmaceutical R&D, and bring greater value and recognition to the industry.


Source: Announcement from the Industrial Development Administration (IDA) of the Ministry of Economic Affairs (MOEA) – Reference List of Biotech and Pharmaceutical Industry Entrusted to Domestic Pharmaceutical R&D Service Companies (download) https://www.ida.gov.tw/ctlr?PRO=application.rwdApplicationView&id=49